Literature DB >> 33308527

Prostatic Artery Embolization in Refractory Hematuria of Prostatic Origin.

Issam Kably1, Vedant Acharya2, Andrew J Richardson3, Shivank Bhatia1.   

Abstract

Hematuria of prostatic origin has multiple etiologies including benign prostatic hyperplasia (BPH), iatrogenic urological trauma, prostate cancer, and radiation therapy. Hematuria secondary to benign prostatic hyperplasia can occur because of the increased vascularity of the primary gland, itself, or because of the vascular re-growth following a transurethral resection of the prostate. Prostatic hematuria usually resolves with conservative measures; however, refractory hematuria of prostatic origin may require hospitalization with treatment with blood transfusions, repeated indwelling urinary catheterization, and continuous bladder irrigation. Prostate artery embolization is an emerging minimally invasive procedural therapy for men with BPH that was originally utilized for the treatment of refractory hematuria of prostatic origin . This article aims to summarize the currently available evidence around prostate artery embolization for the treatment of refractory hematuria of prostatic origin.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  embolization; hematuria; prostatic artery embolization

Year:  2020        PMID: 33308527     DOI: 10.1016/j.tvir.2020.100694

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  2 in total

1.  UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Dean Elterman; Mélanie Aubé-Peterkin; Howard Evans; Hazem Elmansy; Malek Meskawi; Kevin C Zorn; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

2.  Efficacy and Safety of Prostatic Artery Embolization in the Treatment of High Risk Benign Prostatic Hyperplasia and its Influence on Postoperative Life Quality of Patients.

Authors:  Kun Wang; Ming Chen; Yiqing Liu; Weiren Xiao; Yonghong Qian; Xu Liu
Journal:  Front Surg       Date:  2022-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.